Charles H.Arnett Ph.D. (Charlie)

IP Legal Intern

華盛頓 + 1.202.879.3896

聯絡

*Share

Dr. Charles (Charlie) Arnett prosecutes patent applications and manages global patent portfolios in the pharmaceutical and biotech industries. Charlie assists clients with a broad range of services, including preparation and prosecution of patent applications, management of worldwide patent portfolio strategies, performance of due diligence investigations, patentability and validity assessments, and freedom-to-operate analysis. Representative clients include Celgene Corporation, REGENXBIO, and Nuvalent.

Prior to joining Jones Day, Charlie was an NSF Graduate Research Fellow at the California Institute of Technology, where he synthesized and studied model complexes of the nitrogenase active site. He also contributed to the development of a Cu-catalyzed protocol for C-H etherification as an undergraduate at Georgetown University. Charlie has coauthored several peer-reviewed scientific publications, four of which are published in the Journal of the American Chemical Society.

執業經驗

  • Nuvalent establishes global patent portfolios for small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitorsJones Day represents Nuvalent, Inc. in the establishment and prosecution of global patent portfolios related to small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitors for the treatment of cancer.
  • Royalty Pharma acquires Oxlumo™ royalty interest from DicernaJones Day advised Royalty Pharma in the acquisition of an interest in Dicerna’s royalty in Dicerna’s OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments.
    •

    *Before sending, please note:

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.